Stock Ratings / Health Care / BTMD / financials

FTLF (48) ISPR (27) MTEX (33) MDWD (60) ⌘ Pro Terminal →

Biote Corp. (Class A) (BTMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.17 +1.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.17

Biote Corp. (Class A) (BTMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $42.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.17 (+0.12%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 15.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BTMD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY BTMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 15.7% FCF Margin ($30.2M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (21% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 43.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.15-5.2% Next Q

Q2 (-2Q)

Grade C$1.09-1.8% Next Q

Q3 (-1Q)

Grade C$1.07+9.3% Next Q

Current

Grade C$1.17+0.7% Hist 90D α

Trajectory: C- (54) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BTMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, BTMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.29) or 200D SMA ($1.83) invalidates the momentum regime and cuts Target Base ($1.19) toward Bear Floor ($0.93).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BTMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BTMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BTMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$30.2M (15.7% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $185.4M

FY24

Rev $197.2M

FY25

Rev $192.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$192.2M	52%	18.5%	$27.0M	$30.2M	95%
FY 2024	$197.2M	52%	16%	$3.2M	$38.8M	95%
FY 2023	$185.4M	52%	15.5%	$3.3M	$26.9M	85%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BTMD)

✓Walkthrough of BTMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BTMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.30%⚡ TESTING RESISTANCE

2026-10-30O $1.17H $1.20L $1.11C $1.17VOL 65.6K

RES: $1.22SUP: $0.90SMA50: $1.29SMA200: $1.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BTMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BTMD Butterfly Map → + Track BTMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-15.0%/yr Implied 5Y Growth

vs. -2.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BTMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BTMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BTMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BTMD)

Health Care Rank #176 of 1016 ⚔️ FTLF vs BTMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BTMD vs. FTLF, ISPR, MTEX, MDWD)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Biote Corp. (Class A) (BTMD) ranks #176 by composite RQD confidence (62/100, grade C) and #768 by equity capitalization ($42.0M). Within this direct 5-issuer industry benchmark cohort, FTLF leads on earnings valuation at 11.7x trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BTMD currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BTMD ACTIVE Biote Corp. (Class A)	C	62/100	—	—	85.0%	+1.74%	$42.0M	Benchmark Subject
FTLF FitLife Brands Inc.	D	48/100	11.7x	43.1%	5.4%	-4.70%	$74.3M	/ftlf-vs-btmd →
ISPR Ispire Technology Inc.	E	27/100	—	17.8%	-35.0%	-1.44%	$79.1M	/ispr-vs-btmd →
MTEX Mannatech Incorporated	E	33/100	—	74.9%	-35.0%	-2.23%	$16.1M	/mtex-vs-btmd →
MDWD MediWound Ltd.	C-	60/100	—	—	—	+2.21%	$178.9M	/mdwd-vs-btmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819253

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biote Corp. (Class A) (BTMD) reported GAAP revenue of $192.2M (-2.5% vs. FY2024 revenue of $197.2M , and +3.7% cumulative change since FY2023) , GAAP net income of $27.0M, operating cash flow of $35.2M, and free cash flow of $30.2M (-22.2% YoY). On the balance sheet, BTMD closed FY2025 with $107.6M in total assets against $95.8M in total debt (Altman Z-Score: 2.50, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$192.2M	$27.0M	$35.2M	$30.2M	$107.6M	$95.8M
FY2024 (FY)	2024-12-31	$197.2M	$3.2M	$45.2M	$38.8M	$122.4M	$101.2M
FY2023 (FY)	2023-12-31	$185.4M	$3.3M	$26.9M	$26.9M	—	—

3. BTMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Biote Corp. (Class A) (NASDAQ: BTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $1.17 (+1.74% 1D, market cap $42.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BTMD ranks #176 in composite RQD confidence.

How does BTMD compare to FTLF and ISPR in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), BTMD carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, FTLF (FitLife Brands Inc.) holds a D grade (48/100 RQD, P/E 11.7x, ROIC 5.4%, cap $74.3M) and ISPR (Ispire Technology Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $79.1M). Among the 5-stock peer group, FTLF leads on earnings multiple (11.7x) while BTMD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BTMD?

Per BTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819253), Biote Corp. (Class A) generated $192.2M in revenue (-2.5% YoY), $27.0M in net income, and $30.2M in free cash flow against $107.6M in total assets and $95.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BTMD trading relative to its 50-day, 200-day, and 52-week technical levels?

BTMD last traded at $1.17 (+1.74% on volume of 127,002 shares), positioning the stock -9.30% below its 50-day simple moving average ($1.29) and -36.07% below its 200-day simple moving average ($1.83). Across its 52-week range of $1.00 to $2.98, BTMD sits at the 8.6% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.02 to $1.32).

BTMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Biote Corp. (Class A) (BTMD)?

In FY 2025 (10-K), BTMD converted $192.2M of revenue into a 52% gross margin, 18.5% operating margin, and $30.2M in free cash flow (15.7% FCF margin).

Direct Sub-Reports: BTMD RQD Cockpit BTMD 12M Forecast BTMD Earnings & Move BTMD Dividends & DRIP BTMD Insiders & 13F BTMD Whale Options BTMD Profit Sankey BTMD News & Why